Literature DB >> 30123539

Harmonization study of antibodies and platforms for programmed death ligand 1 immunostaining in non-small cell lung cancer: does shuffling couples settle the troubles?

Jumpei Kashima1, Yusuke Okuma2.   

Abstract

Entities:  

Year:  2018        PMID： 30123539      PMCID： PMC6072959          DOI： 10.21037/jtd.2018.06.116

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.

Authors:  Marianne J Ratcliffe; Alan Sharpe; Anita Midha; Craig Barker; Marietta Scott; Paul Scorer; Hytham Al-Masri; Marlon C Rebelatto; Jill Walker
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

3.  Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.

Authors:  J Adam; N Le Stang; I Rouquette; A Cazes; C Badoual; H Pinot-Roussel; L Tixier; C Danel; F Damiola; D Damotte; F Penault-Llorca; S Lantuéjoul
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

4.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

5.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.

Authors:  Tzahi Neuman; Michal London; Juliane Kania-Almog; Anna Litvin; Yaniv Zohar; Ludmila Fridel; Judith Sandbank; Iris Barshak; Gilad W Vainer
Journal:  J Thorac Oncol       Date:  2016-09-21       Impact factor: 15.609

8.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Authors:  Andreas H Scheel; Manfred Dietel; Lukas C Heukamp; Korinna Jöhrens; Thomas Kirchner; Simone Reu; Josef Rüschoff; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Arne Warth; Wilko Weichert; Rieke N Fischer; Jürgen Wolf; Reinhard Buettner
Journal:  Mod Pathol       Date:  2016-07-08       Impact factor: 7.842

9.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Authors:  David L Rimm; Gang Han; Janis M Taube; Eunhee S Yi; Julia A Bridge; Douglas B Flieder; Robert Homer; William W West; Hong Wu; Anja C Roden; Junya Fujimoto; Hui Yu; Robert Anders; Ashley Kowalewski; Christopher Rivard; Jamaal Rehman; Cory Batenchuk; Virginia Burns; Fred R Hirsch; Ignacio I Wistuba
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.